18:54 , Jul 13, 2018 |  BC Week In Review  |  Company News

Pilot supports real-world endpoints as surrogates for OS

Friends of Cancer Research released data on July 10 that support the use of real-world evidence (RWE) outcomes -- including real-world progression-free survival (rwPFS) -- as surrogate endpoints for overall survival to evaluate a treatment's...
15:40 , Jul 12, 2018 |  BC Innovations  |  Translation in Brief

Reviving NK cells

Researchers from the University of Science and Technology of China have identified a key role for TIGIT in NK cell exhaustion that suggests immunotherapies targeting TIGIT may be useful against cancers that have failed to...
22:26 , Jul 10, 2018 |  BC Extra  |  Clinical News

Pilot supports real-world endpoints as surrogates for OS

Friends of Cancer Research released data Tuesday that support the use of real-world evidence (RWE) outcomes -- including real-world progression-free survival (rwPFS) -- as surrogate endpoints for overall survival to evaluate a treatment's long-term effects. In...
23:59 , Jun 21, 2018 |  BC Innovations  |  Product R&D

Tusk’s take on CD25

As companies revisit the potential of IL-2 to aid cancer immunotherapy, Tusk Therapeutics Ltd. has a new take by attacking CD25, a component of the IL-2 receptor with its own storied past. Its antibody could...
02:02 , Jun 9, 2018 |  BioCentury  |  Product Development

POC for cytokines

A body of clinical evidence is emerging that two different approaches to immune-stimulating cytokine therapies could increase efficacy of PD-1 inhibitors in both hot and cold tumors. Oncologists who spoke to BioCentury said, taken together, data...
05:50 , Jun 2, 2018 |  BioCentury  |  Product Development

Breaking from the herd

Behind the block of clinical studies on PD-1 and PD-L1 inhibitors, researchers are casting aside their herd mentality with a wide net of strategies to solve some of the most pressing problems in oncology, such...
15:29 , May 25, 2018 |  BC Week In Review  |  Clinical News

Keytruda improves survival in first-line squamous NSCLC

Merck & Co. Inc. (NYSE:MRK) said Keytruda pembrolizumab plus chemotherapy met the primary endpoints of improving progression-free survival (PFS) and overall survival (OS) in the Phase III KEYNOTE-407 trial as first-line treatment of metastatic squamous...
18:33 , May 23, 2018 |  BC Extra  |  Clinical News

Keytruda improves survival in first-line squamous NSCLC

Merck & Co. Inc. (NYSE:MRK) said Keytruda pembrolizumab plus chemotherapy met the primary endpoints of improving progression-free survival (PFS) and overall survival (OS) in the Phase III KEYNOTE-407 trial as first-line treatment of metastatic squamous...
23:41 , Apr 26, 2018 |  BC Innovations  |  Product R&D

Brake for gas

Elpiscience Biopharmaceuticals Co. Ltd. has emerged from stealth mode with an unconventional bispecific that simultaneously removes the brakes and steps on the gas for antitumor immunity, but only inside tumors. The goal is to upstage...
20:18 , Apr 9, 2018 |  BC Extra  |  Clinical News

Keytruda meets in first-line NSCLC with low PD-L1 expression

Merck & Co. Inc. (NYSE:MRK) added $2.80 to $56.16 Monday after reporting that Keytruda pembrolizumab as monotherapy met the primary endpoint of improving overall survival (OS) in the Phase III KEYNOTE-042 trial as first-line treatment...